Anondita Medicare's recent performance on the NSE SME platform provides a compelling case study of the potential rewards

and inherent risks within the small and medium enterprise (SME) initial public offering (IPO) market. Since listing in

early September 2025 at ₹275.50, a 90% premium over its issue price of ₹145, the stock has surged nearly 500%, reaching

₹867. This rapid appreciation has generated significant returns for early investors, particularly those who secured

allotments during the IPO. An investor who received the minimum retail allotment of two lots, comprising 2,000 shares,

would have seen their investment grow by approximately ₹17.34 lakh in under four months. This performance has positioned

Anondita Medicare as a standout wealth creator in 2025, despite broader market fluctuations.

This surge in value is particularly notable given the mixed performance of SME IPOs overall. While 2025 witnessed a

record number of SME issues entering the Indian stock market (260, compared to 247 in 2024 and 177 in 2023), a

significant proportion of these stocks have struggled to maintain their initial listing prices. Data indicates that

nearly 50% of the 366 total issues (including mainboard IPOs) are currently trading below their issue prices. This

highlights the selective nature of success within the IPO market and the importance of due diligence.

The Anondita Medicare IPO itself was met with substantial investor demand, evidenced by a 301-times subscription rate.

The non-institutional investor (NII) segment demonstrated the most aggressive bidding, with a 531.82-times subscription.

The retail investor portion was subscribed 286.20 times, while the qualified institutional buyer (QIB) segment saw bids

153.03 times the shares on offer. The IPO, a fresh issue of 0.48 crore shares priced between ₹137 and ₹145 per share,

aimed to raise ₹69.50 crore. These funds are earmarked for equipment and machinery purchases, working capital

requirements, acquisitions, and general corporate purposes.

Anondita Medicare, incorporated in March 2024, operates in the manufacturing of flavored male condoms under the brand

name “COBRA.” The company boasts an annual production capacity of 562 million condoms at its Noida, Uttar Pradesh

facility. In addition to domestic sales, Anondita Medicare exports its products to international markets, including

Southeast Asia, Africa, and the Middle East. The company's growth trajectory is intertwined with the demand for its

products both domestically and internationally.

Investors should note that while Anondita Medicare's performance has been exceptional, the SME IPO market is

characterized by volatility and risk. Comprehensive research and consultation with financial experts are essential

before making any investment decisions.